Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuvirtide intensification for poor immune restoration in treated HIV infection
ChiCTR2100053311Phase 4Recruiting
- Sponsor
- Tianjin Second People's Hospital
- Start
- Nov 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of albuvirtide in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) (2 arms), sponsored by Tianjin Second People's Hospital. Primary endpoint: CD4+ T cell count. Started Nov 2021; status: recruiting.
02
Drugs
albuvirtide
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR2100053311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053311.